Compare Amylx Pharmaceuticals Inc (AMLX) vs Hormel Foods Corp (HRL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Hormel Foods Corp — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Hormel Foods Corp trades at $24.52 (market cap $13.61B). The key difference: Hormel Foods Corp is far larger — about 6.9× Amylx Pharmaceuticals Inc's market cap, and Hormel Foods Corp pays a 4.73% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | HRL | |
|---|---|---|
Market Cap | $1.98B | $13.61B |
Sector | Health | Consumer Staples |
52-Week High | $18.70 | $30.51 |
52-Week Low | $7.64 | $19.74 |
Enterprise Value | $1.70B | $15.61B |
Dividend Yield | — | 4.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Hormel Foods (HRL) trades at $24.735, up 1.66% today, with a bearish technical signal but consistent earnings beats in recent quarters. The company maintains a 60-year dividend growth streak, paying $0.29 quarterly, while navigating margin pressures with a 3.82% net income margin. Recent news highlights strategic moves like the Ceratti Brazil sale to sharpen growth focus, though revenue trends remain flat near $12.1B.
Outlook is mixed: valuation appears reasonable (P/E 29.09, P/S 1.11) with analyst consensus at $26.00, but risks include volatile cash flows and competitive pressures. The stock offers income stability via dividends, yet investors face headwinds from inflation and sluggish profit growth, requiring patience for a turnaround.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Hormel Foods Corp
Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →
